Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amphastar Pharmaceuticals Inc AMPH

Healthcare
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed... see more

Recent & Breaking News (NDAQ:AMPH)

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023

Accesswire November 1, 2023

Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes

Accesswire September 13, 2023

Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes

Accesswire September 11, 2023

Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference

Accesswire August 31, 2023

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023

Accesswire August 8, 2023

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023

Accesswire August 2, 2023

Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly

Accesswire June 30, 2023

Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference

Accesswire May 31, 2023

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023

Accesswire May 9, 2023

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023

Accesswire May 3, 2023

Lilly to Divest BAQSIMI to Amphastar

PR Newswire April 24, 2023

Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023

Accesswire April 24, 2023

Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

Accesswire April 12, 2023

Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg

Accesswire March 8, 2023

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2022

Accesswire February 28, 2023

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023

Accesswire February 22, 2023

Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference

Accesswire November 22, 2022

Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference

Accesswire November 10, 2022

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2022

Accesswire November 7, 2022

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022

Accesswire October 28, 2022